Your browser doesn't support javascript.
loading
Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation.
Shan, Chuan-Kun; Du, Yi-Bo; Zhai, Xiao-Tian; Wang, Yue-Xuan; Li, Yi; Gong, Jian-Hua; Ge, Zhi-Juan; Liu, Xiu-Jun; Zhen, Yong-Su.
Afiliação
  • Shan CK; NHC Key Laboratory of Biotechnology of Antibiotics, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Du YB; NHC Key Laboratory of Biotechnology of Antibiotics, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhai XT; NHC Key Laboratory of Biotechnology of Antibiotics, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wang YX; NHC Key Laboratory of Biotechnology of Antibiotics, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Li Y; NHC Key Laboratory of Biotechnology of Antibiotics, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Gong JH; NHC Key Laboratory of Biotechnology of Antibiotics, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Ge ZJ; NHC Key Laboratory of Biotechnology of Antibiotics, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Liu XJ; NHC Key Laboratory of Biotechnology of Antibiotics, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. liuxiujun2000@imb.pumc.edu.cn.
  • Zhen YS; NHC Key Laboratory of Biotechnology of Antibiotics, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. zhenysm@126.com.
Cancer Chemother Pharmacol ; 87(3): 425-436, 2021 03.
Article em En | MEDLINE | ID: mdl-33388950
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Mamárias Animais / Receptor de Morte Celular Programada 1 Tipo de estudo: Risk_factors_studies Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Mamárias Animais / Receptor de Morte Celular Programada 1 Tipo de estudo: Risk_factors_studies Limite: Animals Idioma: En Ano de publicação: 2021 Tipo de documento: Article